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Abstract Although cardiac arrest (CA) constitutes a major
health problem with dismal prognosis, no specific drug therapy
has been shown to improve survival to hospital discharge. CA
causes adrenal insufficiency which is associated with poor out-
come and increased mortality. Adrenal insufficiency may man-
ifest as an inability to increase cortisol secretion during and after
cardiopulmonary resuscitation (CPR). Several studies suggest
that glucocorticoids during and after CPR seem to confer benefits
with respect to return of spontaneous circulation (ROSC) rates
and long term survival. They have beneficial hemodynamic
effects that may favor their use during CPR and in the early
post-resuscitation period. Moreover, they have anti-
inflammatory and anti-apoptotic properties that improve organ
function by reducing ischemia/reperfusion (I/R) injury. However,
glucocorticoid supplementation has shown conflicting results
with regard to survival to hospital discharge and neurological
outcome. The purpose of this article is to review the pathophys-
iology of hypothalamic-pituitary-adrenal (HPA) axis during
CPR. Furthermore, this article reviews the effects of glucocorti-
coids use during CRP and the post-resuscitation phase.
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Introduction
Although the initial success rate of cardiopulmonary resusci-
tation (CPR) and hospital discharge with good neurological
condition have increased over the past years, the overall
results are however still quite disappointing [1, 2]. The use
of vasopressors has long been a mainstay of therapy during
CPR [3]. However no specific drug therapy has been shown to
improve survival to hospital discharge after cardiac arrest
(CA) [4].
Emerging evidence demonstrate that CA could cause CA-
related adrenal insufficiency that is highly correlated with
poor outcome and increased mortality [5–7]. Moreover, adre-
nal insufficiency may manifest as an inability to increase
cortisol secretion during and after CPR [6, 8]. Glucocorticoids
have beneficial hemodynamic and anti-inflammatory effects
that may favor their use during CPR and in the early
post-resuscitation period. They maintain hemodynamic
stability by enhancing vasopressor effects and increasing
perfusion pressures during and after CPR [9, 10]. Fur-
thermore, they have anti-inflammatory and anti-apoptotic
properties that prevent organ toxicity [11]. However, gluco-
corticoid treatment with low, medium, and high doses has
shown conflicting results with regard to neurological outcome
[12].
The purpose of this article is to review the pathophysiology
of hypothalamic-pituitary-adrenal (HPA) axis during CPR.
Furthermore, this article reviews the effects of glucocorticoids
use during CPR and the post-resuscitation phase.
Physiology of the HPA Axis
Acute stress activates both the sympathetic nervous system to
release catecholamines as well as the HPA axis [13]. Stressful
signals like hypoxemia and hypotension are integrated by the
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hypothalamus which in turn increases the release of
corticotropin-releasing hormone (CRH). CRH circulates to
the anterior pituitary gland, where it stimulates the release of
adrenocorticotropin (ACTH). The adrenal cortex is stimulated
by ACTH to release glucocorticoid (cortisol) [14]. Arginine
vasopressin (ADH) is also a stress hormone, released from the
posterior pituitary lobe which stimulates to a lesser degree the
release of ACTH from the anterior pituitary lobe [15, 16]. The
decrease in cortisol release is the result of a negative feedback
inhibition loop, which is triggered by a prolonged elevation of
serum cortisol. Utilizing the above-mentioned mechanisms,
the body controls the secretion of cortisol by keeping it within
relatively narrow limits and it responds to stress with in-
creased secretion of cortisol.
It is known that cortisol is the predominant corticosteroid
produced in the human body. Nevertheless, only free cortisol
is biologically active; more than 90 % of the circulating
cort isol is bound to proteins, predominant ly to
corticosteroid-binding globulin (CBG), and, to a lesser extent,
to albumin [17]. Glucocorticoids exert their effects by binding
to and activating an intracellular glucocorticoid receptor (GR)
protein (Fig. 1), as well as a mineralocorticoid receptor protein
[18, 19]. Intracellular metabolism by 11β-hydroxysteroid
dehydrogenase controls the availability of glucocorticoids
for binding to the glucocorticoid and mineralocorticoid
receptors [19]. Moreover, glucocorticoids may directly
interact with cell membranes, as they dissolve into lipid mem-
branes and affect the activity of membrane-associated proteins
[19].
Pathophysiology of the HPA Axis During CA and CPR
Stress imposed byCA results in an acute stress response that is
mediated by the activation of the HPA axis. Although an intact
HPA axis is demonstrated by increased levels of circulating
cortisol, the response of the adrenal gland is inadequate related
to the degree of hypoxic stress associated with CA [6]. The
no-reflow phase of CA and the low flow of CPR results
in inadequate perfusion of the adrenal cortex and im-
pairs the integrity of the HPA axis [20]. The ischemic
injury of the adrenal gland leads to adrenal insufficien-
cy, which may be manifested as an inability to increase
cortisol secretion during and after CPR. The homeosta-
sis of the neuroendocrine system is damaged, because
cortisol is not secreted in response to ACTH, thus
resulting in a low concentration of serum cortisol and
in high concentrations of the plasma ACTH and ADH.
Studies have shown that cortisol levels are relatively
low during and after CPR, indicating a dysfunction of
the adrenal gland [6, 7]. Schultz et al. pointed out that
there was no serum cortisol response at either 6 or 24 h
after resuscitation, indicating that the adrenal gland was
refractory to ACTH [6]. The low response of the adre-
nal glands to ACTH in non-survivors indicates a greater
suppression of the adrenal function in comparison to the
one observed in survivors [7].
Cerebral damage after CA is predominantly located in
‘watershed’ regions of the brain, including the hippo-
campus [21]. The hippocampus is a key regulatory
region for HPA axis negative feedback; therefore, dam-
age from CA/CPR may disrupt negative feedback [22].
Moreover, the HPA axis is extremely sensitive to a
cessation of blood flow [23] and studies have shown
that prolonged intervals of no flow result in greater
ischemic organ injury to the HPA axis. Lindner et al.
noted that the interval from collapse to the start of CPR
was negatively correlated with serum cortisol concentra-
tions during resuscitation, thus implying an impaired
cortisol release with CA [24]. In addition to this, Pene
et al. reported that a long interval before initiation of
CPR was associated with occurrence of relative adrenal
dysfunction [25].
During CPR and the immediate post-resuscitation phase,
pro-inflammatory cytokines (TNF-a, IL-1, IL-6) are released,
which dysregulate the axis and lead to adrenal insufficiency as
reflected by low cortisol levels [24, 26]. The pituitary response
to the hypothalamic corticotropin releasing hormone and the
synthesis and release of cortisol from ACTH-stimulated adre-
nocortical cells is suppressed by the systemic inflammation
[27]. Moreover, plasma ACTH becomes biologically ineffec-
tive which leads to suppression of the synthesis and release of
cortisol from ACTH-stimulated adrenocortical cells (Fig. 2)
[20].
Fig. 1 Main mechanism of action of glucocorticoids. Glucocorticoids
bind to GRwithin the cytoplasm of the cell. Upon glucocorticoid binding,
the activated GR translocates into the nucleus. GR binds to GRE and
affects protein synthesis at the transcription step GR glucocorticoid re-
ceptor,GRE glucocorticoid response element, a stretch of DNA that binds
the GR and activates gene transcription
478 Cardiovasc Drugs Ther (2014) 28:477–488
Effect of Serum Cortisol Level on the Outcome
of Cardiopulmonary Resuscitation
It is known that stress states are often accompanied by in-
creased circulating cortisol concentrations. Hypercortisolemia
in critical illness has been attributed both to stress-induced
activation of the HPA axis and to impaired cortisol metabo-
lism [28]. However, in CA ischemic injury of the HPA axis
impairs adrenal cortisol release with subsequent decrease in
serum cortisol levels. The inadequate response of the HPA
axis to the severe stress of CA compared to other stress states
makes glucocorticoid supplementation important during CPR.
Most studies have shown that adrenal insufficiency may man-
ifest as low serum cortisol concentration during CPR and that
serum cortisol levels are lower in non-survivors of CA than in
survivors [6, 24, 29]. In a prospective cohort study, Tavakoli
et al. measured serum cortisol levels 5 min and 1 h after return of
spontaneous circulation (ROSC) in 50 successfully resuscitated
patients. They showed that serum cortisol levels were signifi-
cantly higher in neurologically intact survivors than non-survi-
vors. The authors suggested that serum cortisol levels may serve
as a predictor of survival in successfully resuscitated victims of
CA [29]. Schultz et al. conducted a prospective study with 205
adult patients presentingwith CA and documented an increase in
serum cortisol concentrations in survivors during the first 24 h
post-ROSC. It was therefore inferred that inadequate cortisol
concentrations may play a role in the hemodynamic instability
commonly seen after ROSC [6]. It was also suggested that
physiologic replacement of glucocorticoids during CPR and
during the first 24 h after ROSC may be warranted [6]. Similar
findings were demonstrated by Lindner et al.; they reported that
during CPR, cortisol concentration was significantly higher in
resuscitated patients than in non-resuscitated ones. In addition,
according to the above mentioned study no significant correla-
tion between cortisol level and blood pressure in the immediate
post-resuscitation phase could be found. However, it is possible
that factors that were not determined by the study protocol could
have led to this result. Firstly, the study protocol did not allow a
precise determination of the relative contribution of post-
resuscitation hemodynamic support to the lack of correlation
between cortisol level and blood pressure in the post-
resuscitation phase. Furthermore, a possible variability of the
fraction of protein-bound cortisol, potentially leading to a vari-
able concentration of the biologically active, unbound cortisol,
was also not determined [24].
Catecholamines released due to adrenosympathetic dis-
charge induce vasoconstriction and increase vital organ per-
fusion pressures fascilitating thus ROSC [3]. However, in the
cardiac arrest setting, the overwhelming endogenous catechol-
amine release results in intense vasoconstriction and de-
creased microvascular blood flow [3]. Moreover, activation
of b1-adrenoreceptors increases myocardial oxygen consump-
tion [3]. These adverse effects of catecholamines lead to
hemodynamic instability and poor survival outcome [3]. In
Fig. 2 The hypothalamic-
pituitary-adrenal axis during
cardiac arrest CRH corticotropin-
releasing hormone, ACTH
adrenocorticotropin
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addition to the action of catecholamines, the stress hormone
response during cardiac arrest also includes the release of
vasopressin. Vasopressin is a non-adrenergic vasopressor
which stimulates the release of ACTH from the anterior pitu-
itary lobe [15] and results in higher adrenal gland blood flow
compared with adrenaline, which increases cortisol release
[30]. Studies have shown that increased plasma ACTH and
cortisol concentrations induced by vasopressin may maintain
hemodynamic stability and improve ROSC rate [16, 31].
Kornberg experimented on 14 pigs in order to compare plas-
ma concentrations of ACTH and cortisol, after epinephrine or
vasopressin administration in an experimental animal model
of CPR. He reported a higher rate of ROSC (100 % vs. 13 %)
after the administration of vasopressin than after the adminis-
tration of epinephrine, despite an almost equal coronary per-
fusion pressure. The authors reported that the augmented
release of cortisol associated with vasopressin may enhance
myocardial function during CPR. Although the number of the
animals tested was relatively small to lead to a safe conclu-
sion, it is clear that in this study treatment with vasopressin
improved survival as well as hemodynamic stability, justify-
ing the need for further research in this area [16]. Additionally,
Lindner et al. showed that serum arginine vasopressin and
ACTH levels were higher during CPR in successfully resus-
citated patients compared to non-resuscitated patients. More-
over, plasma adrenaline and noradrenaline concentrations
were significantly higher in patients in whom resuscitation
failed than in resuscitated patients, indicating that excessive
adrenosympathetic discharge may be associated with poor
prognosis after CA [31].
Actions of Glucocorticoids
Glucocorticoids have metabolic properties. Their various ef-
fects include alterations in carbohydrate, lipid, and protein
metabolism and maintenance of electrolyte and fluid balance
[26]. Glucocorticoids increase blood glucose concentrations
and facilitate the delivery of glucose to cells during acute
stress [26], increasing the rate of hepatic gluconeogenesis
and inhibiting adipose tissue glucose uptake [27]. Glucocor-
ticoids also supply energy to the cell by stimulating free fatty-
acid release from adipose tissue and amino-acid release from
proteins. In addition, they promote redistribution of body fat
and facilitate the effect of adipokinetic agents in eliciting
lipolysis of triglycerides in adipose tissue.
Glucocorticoids have a permissive effect on the synthesis
of catecholamines and vasoactive peptides [20]. The mecha-
nism postulated includes a cortisol induced inhibition of
catechol-O-methyl transferase and a blockade of catechol-
amine reuptake [32]. Glucocorticoids effects on synthesis of
catecholamines and catecholamine receptors are partially re-
sponsible for the positive inotropic effects of these hormones
[33]. Moreover, they increase systemic vascular resistance
[34] and mediate maintenance of peripheral vasomotor tone
by facilitating catecholamine-induced vasoconstriction [35].
Glucocorticoids also decrease the production of nitric oxide, a
major vasorelaxant and modulator of vascular permeability
[36].
Glucocorticoids also have anti-inflammatory and immuno-
suppressive effects [37]. They attenuate the generation and
release of inflammatory cytokines i.e., interleukin [IL-1, IL-3,
IL-6, tumor necrosis factor [TNF-a]) [38]. Additionally, they
decrease the accumulation and function of macrophages and
neutrophils at inflammatory sites [39]. They counteract the
acute inflammatory effects on the microcirculation, resulting
in vasoconstriction, reduction of edema and a decreased rate
of leucocyte adhesion to the injured areas [19].
Effects of Glucocorticoids Administration During CPR
Glucocorticoids During CPR in Laboratory Models
Glucocorticoid administration in experimental studies has
shown positive results. In a rat model stimulating CA, a dose
response investigation of two hydrocortisone dosages
(0. 25 mg and 0. 5 mg) compared with normal saline as
placebo, showed that 0. 25 mg hydrocortisone was the most
effective dose in regard to increasing ROSC rates (p<0. 05).
The authors suggest that cortisol improved ROSC by enhanc-
ing the cardiovascular effects of epinephrine. However, this
study had a major limitation. Rats were anesthetized with
pentobarbital prior to CA in order to prevent a hyperadrenal
response and it has been acknowledged that pentobarbital
induces the liver enzyme system while stimulating steroid
clearance, which may have transiently decreased corticoste-
roid levels in the rats [40]. These results were further support-
ed by a rat model of asphyxial CA treated with methylpred-
nisolone. In this study 20 rats were randomly assigned to 4
treatment groups. The first group received placebo and the
second methylprednisolone before CA. The two other groups
received placebo and methylprednisolone respectively, after
CA. Animals that received methylprednisolone after CA had
shorter CPR times required for ROSC although it was not of
statistical significance. Moreover, they did not require norepi-
nephrine for vasopressor support and achieved a statistically
significant recovery of EEG activity compared to the other
animals [41] (Τable 1).
Clinical Data with Glucocorticoids During Cardiac Arrest
The high mortality rate that has been observed in patients with
CA-related adrenal dysfunction and the positive correlation of
cortisol levels with survival in CPR raised the question of
glucocorticoid supplementation during CPR [6]. The use of
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glucocorticoids in CPR was first investigated in 1976 with the
use of dexamethasone in pulseless electrical activity (PEA).
White et al. reported the use of a single intravenous bolus of
100 mg dexamethasone in five patients with PEA. They
showed a success in rhythm correction and increase in cardiac
output after dexamethasone administration in resuscitation
[42]. Moreover, in 1979, White reported that supplementation
of corticosteroids in PEA increased ROSC rate and long term
survival. However, this study exhibited several limitations as
it was a retrospective study with no assessment of CPR
quality. Moreover, patients with pseudo-pulseless electrical
activity were also likely included in the study [43]. Further-
more, in a small (n=29) prospective, randomized study of
patients with pre-hospital bradyasystolic CA, a larger propor-
tion of patients treated with dexamethasone (n=17) were
successfully resuscitated and discharged, compared to patients
treated with saline (n=12). However, this difference was not
statistically significant [44]. Paris et al. conducted a prospec-
tive, randomized study with administration of 100 mg dexa-
methasone in patients with PEA in the pre-hospital setting.
They failed to demonstrate any benefit from the administra-
tion of dexamethasone in PEA [45]. However, the aforemen-
tioned studies demonstrated the effects of glucocorticoids in
small sample size studies and did not provide information on
the effect of glucocorticoid treatment on CA rhythms other
than PEA.
This prospective and non-randomized trial evaluated the
effect of hydrocortisone in ROSC rates. In this study hydro-
cortisone or placebo were given upon patient arrival to the
emergency department. The results showed statistically sig-
nificant increases in ROSC rates with 100 mg hydrocortisone
(90 % vs 50 %, p=0. 045). Additionally, serum cortisol levels
were not correlated with ROSC rates. Nevertheless, there was
no significant difference between the two groups in terms of
short-term survival and hospital discharge [10]. These find-
ings are in agreement with previous studies which showed that
administration of glucocorticoids improved ROSC rates
through supplying adequate serum cortisol levels [24, 29].
Moreover, the authors reported that the incidence of electro-
lyte disturbances, infection, and GI tract bleeding in the early
phase after ROSC did not increase with hydrocortisone use.
However this study had several limitations as it was non-
randomized and open-labeled and could potentially suffer
from selection bias. Moreover, this pilot study had a small
sample size and did not assess glucocorticoids efficacy
with respect to neurologically favorable survival to hospital
discharge [10].
Vasopressin augments the release of cortisol and improves
the rate of ROSC compared to epinephrine during CPR in an
animal study [16]. Therefore studies investigated the admin-
istration of stress hormone “cocktails” in order to improve the
outcome of patients in cardiac arrest. In a double-blinded
Table 1 Summary of studies regarding the use of glucocorticoids in the setting of cardiac arrest
Study Year Material Result
Mentzelopoulos
et al. [8]
2013 Prospective randomized clinical study Combined vasopressin- epinephrine and methylprednisolone during
CPR and hydrocortisone administration in post-resuscitation period,
hydrocortisone in post-resuscitation shock, resulted in improved
survival to hospital discharge with favorable neurological status
Tsai et al. [9] 2007 Prospective non randomized clinical study Hydrocortisone administration during CPR improved ROSC rate
Jastremski et al. [11] 1989 Prospective non-randomized
clinical study
Glucocorticoid treatment after ROSC failed to demonstrate a beneficial
effect on survival rate and neurological function
Smithline et al. [38] 1993 Rat model of VF-induced CA Hydrocortisone administered during CPR significantly increased ROSC rate
Katz et al. [39] 1989 Rat model of asphyxia- induced CA Methylprednisolone given post CA facilitate ROSC and return of EEG activity
White [19] 1976 5 patients with pulseless
idioventricular rhythms
Dexamethasone administered during CPR corrected rhythm and
increased cardiac output
White et al. [40] 1979 24 patients with pulseless
idioventricular rhythms
Dexamethasone administered during CPR increased ROSC rate and
long term survival
Schwitzer [41] 1983 Prospective randomized clinical study Dexamethasone administered during CPR improved initial
resuscitation (ROSC) and hospital discharge
Paris et al. [42] 1984 Prospective randomized clinical study Dexamethasone administration failed to demonstrate a beneficial
effect on long term survival
Mentzelopoulos
et al. [43]
2009 Prospective randomized clinical study Combined vasopressin- epinephrine and methylprednisolone during
CPR and hydrocortisone administration in post-resuscitation period
improved ROSC and survival to hospital discharge
Grafton et al. [44] 1988 Retrospective non-randomized
clinical study
Glucocorticoid administration failed to demonstrate a beneficial effect
on survival or neurological recovery
CPR cardiopulmonary resuscitation, ROSC return of spontaneous circulation, CA cardiac arrest
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randomized single center study, 100 patients with CA were
treated with either the combination of epinephrine and vaso-
pressin during CPR and glucocorticoid supplementation dur-
ing and after CPR or epinephrine alone during CPR and no
steroids. Patients who received the drug combination had more
frequent ROSC (81 vs 52 %, p=0. 003) and improved survival
to hospital discharge (19 % vs 4 %, p=0. 02) vs patients who
received only epinephrine. Furthermore, patients who received
hydrocortisone in the post-resuscitation period had improved
survival to hospital discharge (30 % vs 0 %, p=0. 02), im-
proved hemodynamics and central venous oxygen saturation
compared to patients who received placebo. Moreover, the
authors pointed out that glucocorticoid administration in-
creased the efficacy of vasopressors in maintaining adequate
perfusion pressures. Glucocorticoids enhanced the inotropic
actions of catecholamines and maintained vascular tone [46].
However, this study only refers to in-hospital CA. Out-of-
hospital trials must be conducted, given the different natures
of these two populations. It must also be taken into account that
the issue of chest compression quality was not addressed in this
study. Moreover, patients were given a combination of vaso-
pressors with glucocorticoids, which made difficult to isolate
the effect of glucocorticoids on the outcome. Thus, it is unclear
if these findings were related to corticosteroid supplementation
or the combination of the medications used [46].
In a randomized, double-blind, placebo-controlled study
conducted by Mentzelopoulos, 268 patients with CA were
randomly assigned to receive either epinephrine and vasopres-
sin during the first five CPR cycles (n=130), or epinephrine
plus saline placebo (n=138). During the first CPR cycle after
randomization patients in the epinephrine, vasopressin, meth-
ylprednisolone group received methylprednisolone (40 mg)
compared to saline placebo in the control group. Shock after
resuscitation was treated with stress-dose hydrocortisone in the
epinephrine, vasopressin, methylprednisolone group, (n=76)
or with saline placebo (n=73). The combination of vasopressin
and epinephrine along with methylprednisolone during CPR
and hydrocortisone in post-resuscitation shock, resulted in
improved survival to hospital discharge with favorable neuro-
logical status, compared with epinephrine and saline placebo
(p=0. 02). The authors suggested that methylprednisolone
during CPR conferred benefits with respect to hemodynamics
by potentiating the vasoconstrictive effects of vasopressors [9].
However, other studies show conflicting results regarding
neurological outcome. In a retrospective comparison of low,
medium and high steroid dose treatment to placebo in 191
patients with 8 h of ROSC after CA, the outcomes were
similar with respect to one year mortality or neurological
recovery (p=NS). The authors concluded that glucocorticoid
treatment was not likely to be beneficial after CA. However,
this study had limitations. There were differences between the
steroid-treated and the non-steroid treated groups with respect
to baseline characteristics and CA etiology potentially
favoring the no steroid-group. Moreover, this study evaluated
a variable steroid treatment with low, medium, and high doses
and not a stress-dose steroid supplementation [12]. Further-
more another non-randomized retrospective study examined
the effect of steroid treatment on the outcome of 458 consec-
utive patients admitted after out-of-hospital CA. In that study
patients were assigned to either receive glucocorticoids or
saline. No significant differences in survival or neurological
recovery were identified [47]. However, the aforementioned
studies both exhibit limitations, as they were retrospective and
non-randomized. Moreover, there was a variation in the dose
of steroids as well as in the duration of steroid treatment. In
addition to that, the protocol of the first study [12] included
post-resuscitation hyperventilation, which could compromise
cerebral perfusion and adversely affect the neurological out-
come. Finally, in the second study there was no pre-specified
determination of hemodynamic targets [47]. Thus, the above
methodological and clinical practice differences could possi-
bly explain the discrepancy in the results regarding the neu-
rological outcome with recent studies [9, 46]. Large, multi-
center, randomized, placebo-controlled studies must be con-
ducted in order to further evaluate the effect of glucocorticoid
administration in global cerebral ischemia.
Several studies have addressed the relationship between
timing of glucocorticoid administration and outcome of
CPR. Glucocorticoid administration within 22 min after CA
showed a higher ROSC rate in patients with witnessed CA (9).
Moreover, in another study glucocorticoid treatment within
8 h after ROSC did not improve neurological recovery. The
authors suggest that the negative outcome of CPR was related
to late administration of glucocorticoids (12). Furthermore,
Paris et al. failed to demonstrate any benefit from the admin-
istration of dexamethasone in PEA in the pre-hospital setting.
They suggested that further studies with earlier and higher
doses of glucocorticoids must be conducted [45].
Mentzelopoulos et al. showed that a combination of vasopres-
sors with glucocorticoid administration during CPR resulted
in improved hemodynamics and survival. Although these
results cannot be attributed solely to methylprednisolone
[46], early CPR drug administration might improve resuscita-
tion outcome, especially in out-of-hospital CA [48, 49]. Fur-
ther studies must be undertaken in order to clarify whether
early administration of glucocorticoids could improve the
outcome of patients resuscitated after CA (Τable 1).
Post-Cardiac Arrest Syndrome
Glucocorticoids and Post-Resuscitation Myocardial
Dysfunction
Post-resuscitation myocardial dysfunction is characterized by
impaired contractile function and variable diastolic
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dysfunction, which resolve within hours or days after ROSC
[50]. I/R injury leads to generation of reactive oxygen species
(ROS). ROS leads to lipid peroxidation products and oxida-
tively modified proteins. Free radical-mediated oxidation of
membrane phospholipids and proteins is associated with de-
struction of critical biomembrane structures and is an impor-
tant mechanism in the pathophysiology of myocardial dys-
function. Glucocorticoids reduce peroxidation of lipids and
proteins and stabilize cell membranes [51, 52]. They attenuate
oxidative stress and therefore enhance recovery of function in
post-ischemic, reperfused myocardium [53].
The release of cytochrome c from mitochondria to cyto-
plasm plays an important role in the development of I/R injury
[54]. Cytochrome c is an essential component of the mito-
chondrial respiratory chain. It is a soluble protein, attached to
the inner mitochondrial membrane [55]. During reperfusion
the inner transmembrane potential is decreased and is follow-
ed by an increase in the permeability of the outer mitochon-
drial membrane with subsequent release of cytochrome c from
the intermembranous space into the cytoplasm. This mito-
chondrial permeability transition followed by cytochrome c
release may trigger apoptosis [56]. Studies have demonstrated
that apoptosis significantly contributes to a reduction of the
contractile response of cardiomyotes with reperfusion of is-
chemic myocardium [57]. Glucocorticoids may reduce the
release of cytochrome c from mitochondria and attenuate
apoptosis. Moreover, glucocorticoid-induced attenuation of
myocardial apoptosis might improve post-ischemic cardiac
function [58].
Furthermore, mitochondrial calcium overload during reper-
fusion is an important mediator of post-resuscitation myocar-
dial dysfunction [50]. Excessive Ca2 influx within mitochon-
dria during I/R injury causes inhibition of mitochondrial ATP
production [59] and induces cardiomyocyte apoptosis [60]. In
addition, calcium influx during ischemia and reperfusion ac-
tivates calcium-dependent proteases which are implicated in
the degradation of cytoskeletal and contractile proteins in
myocytes and therefore compromise ventricular function
[61]. Glucocorticoids have the ability to accumulate calcium
and preserve calcium homoestasis. Besides, they protect mi-
tochondria from utilizing their high-energy compounds to
continuously pump calcium and also allow the resumption
of ATP synthesis. In this way they protect hypoxic mitochon-
dria to remain not only ultra-structurally intact, but also func-
tionally intact [62].
Myocardial dysfunction after CA has been attributed to the
activation of the inflammatory cascade and to subsequent
leukocyte-mediated injury. IL-6 is released during I/R injury
and enhances neutrophil-endothelial adherence and subse-
quent reperfusion injury [63]. The cytokines interleukin IL-
1, IL-6, IL-8 and TNF-a, synergistically depress myocardial
contractile function [64]. They exert a negative inotropic
effect probably mediated by nitric oxide (NO). Studies have
shown that IL-6 inhibited myocardial contractility through
production of NO, suggesting thus that the production of IL-
6 might be a pathogenic factor in the stunned myocardium
[65]. Moreover, IL-1 and TNF-a induce down-regulation of
adrenergic responsiveness in the myocardium. They inhibit
cardiac contractile responsiveness to b-adrenergic stimulation,
which may contribute to reversible impairment of cardiac
function [66]. Glucocorticoids have anti-inflammatory effects
which lead to a repression of pro-inflammatory cytokines and
leukocyte adhesion [67]. In that way they enhance the func-
tion of the myocardium in the acute setting of myocardial I/R
injury [68].
Glucocorticoids may also have positive inotropic and va-
sodilator properties [43, 69]. By binding to glucocorticoid
receptor (GR), they activate endothelial nitric oxide synthase
(eNOS), leading to an increased production of nitric oxide.
Nitric oxide possesses anti-inflammatory and vasodilatory
properties [69]. Vasodilation leads to the reduction of afterload
and enhances the recovery of a post-ischemic, reperfused
myocardium. Glucocorticoids also have a positive inotropic
effect and may enhance the contractile function of myocardi-
um during I/R injury [43]. Moreover, glucocorticoids exert a
direct effect on electrical–mechanical coupling in a hypo-
perfused myocardium and improve cardiac output [53].
Although the results of experimental studies regarding the
cardioprotective role of glucocorticoids are quite encouraging,
attention is required at the case of extrapolating the present
experimental results to the clinical situation. Factors that affect
glucocorticoid treatment like dose, timing and duration of
administration, free cortisol level, effect-site concentration,
level of downregulation of glucocorticoid receptors, metabo-
lism and clearance rates, and even concurrent treatment may
affect the efficacy of glucocorticoid treatment in clinical stud-
ies as they cannot be effectively controlled or measured [53,
67, 68]. As a result, this may lead to a discrepancy in results
between experimental and clinical studies.
The Beneficial Role of Glucocorticoids in Systemic
Ischemia/Reperfusion Response
The recovery of spontaneous circulation after CA leads to a
global systemic I/R syndrome [70]. I/R initiates an acute
inflammatory response contributing to post-resuscitation
shock [24]. It is characterized by the release of suppressive
cytokines (i.e., interleukin IL-1, IL-2, IL-3, IL-6, TNF-a) [38]
suppression of the adrenal function and activation of coagu-
lation pathways in the microcirculation [71].
Post-resuscitation shock shares common features with sep-
tic shock such as reversible myocardial dysfunction, vasodi-
latation and plasma cytokine elevation [72]. In the post-
resuscitation phase adrenal insufficiency induces hypotension
and reduces the effectiveness of vasopressors [73]. These
hemodynamic alterations [74] render patients at high risk for
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acute organ hypo-perfusion and multiorgan system dysfunc-
tion [75]. The relationship between adrenal dysfunction and
post-resuscitation shock was analyzed in several studies. Kim
et al. reported in a prospective study that relative adrenal
insufficiency may be associated with increased mortality rate in
patients with ROSC [26]. Two other studies reported that low
cortisol levels caused organ damage by reperfusion injury [7,
29]. Hekimian et al. reported that patients who die of early
refractory shock after CPR may have an inadequate adrenal
response [76]. Moreover, Pene et al. assessed the prevalence of
relative adrenal insufficiency in patients successfully resuscitated
after CA and its prognostic role in I/R syndrome. They showed
that the presence of relative adrenal insufficiency was predictive
ofmultiple organ failuremortality. However, the authors failed to
demonstrate adrenal dysfunction as a poor prognostic factor in
cases of post-resuscitation hemodynamic instability, due to a
small sample size [25]. De Jong et al. argued against adrenal
insufficiency contributing to a poor outcome. They suggested
that post-resuscitation shock after successful CPRwas associated
with greater activation of the HPA axis and that low serum
cortisol levels did not predict mortality. However, methodolog-
ical differences could possibly explain the discrepancy of the
results between this study and the aforementioned studies, as De
Jong et al. evaluated free cortisol levels versus total cortisol
levels. Moreover, differences in body temperature management
may have activated the HPA axis to a different degree. Further-
more, in long-term survivors, the hemodynamic effects of hypo-
thermia per se in the post-resuscitation phase may have
counteracted the activation of the HPA axis [77].
Most studies concerning the effects of glucocorticoids were
based on septic shock models. Glucocorticoids improved
cardiovascular stability reduced catecholamine dosages and
shortened the duration of shock in patients with sepsis [72, 78,
79]. Recent prospective randomized trials have shown that
treatment with low-dose hydrocortisone significantly reduced
mortality and the need for vasopressor therapy in patients with
vasopressor-dependent septic shock [80, 81]. Due to the sim-
ilarities between post-resuscitation shock and septic shock,
studies evaluated a potential benefit of glucocorticoid admin-
istration for patients with hemodynamic instability following
CA [75, 82]. Mentzelopoulos et al. showed increased efficacy
of adding vasopressin and methylprednisolone to epinephrine
during CPR and treating post-resuscitation shock with stress-
dose hydrocortisone. According to this study, patients in the
vasopressin-steroids-epinephrine group had more frequent
ROSC and attenuated post-resuscitation systemic inflammatory
response and organ dysfunction. In addition, it is shown that
increasedMAP in the post-resuscitation phase induced hemody-
namic stability and improved the outcome of post-resuscitation
shock [46]. In another study, the combination of glucocorticoids
with vasopressors during CPR and glucocorticoids administra-
tion in the early post-resuscitation phase improved myocardial
function and post-arrest MAP leading to improved survival and
neurological outcome [9]. Although there is evidence that glu-
cocorticoids have beneficial effects with regard to post-
resuscitation shock, high quality human trials are still lacking.
Further studies are needed to investigate the effect of glucocor-
ticoid supplementation in the post-resuscitation period.
Glucocorticoids in Post-Cardiac Arrest Brain Injury
I/R syndrome leads to free radical formation which is a major
component regarding the pathophysiology of post-CA brain
injury [83]. Free radical-induced lipid peroxidation reduces
ionic pump activity and increases cell membrane permeability.
The integrity of sub-cellular brain membranes structure and
function is disrupted [84]. Glucocorticoids have beneficial
antioxidant and anti-apoptotic properties and reduce free-
radical lipid peroxidation [11, 85–87]. They activate the
sodium-potassium pump [88] and stabilize cellular mem-
branes exposed to oxidative stress [11]. Studies have shown
that glucocorticoids administration during CA preserved the
integrity of membranes structure and improved brain function
[41]. In that way they prevent irreversible functional and
structural damage in brain [89].
Furthermore, the systemic inflammatory response leads to
disturbances in cerebral vascular autoregulation. Alterations
in capillary permeability induce vasogenic brain edema and
aggravate brain injury [90]. Glucocorticoids exert anti-
inflammatory effects, inhibit the adhesion of leukocyte to
endothelium and therefore protect the endothelial cells [88].
In that way they enhance capillary permeability, maintain the
stability of the vascular microcirculation and improve local
blood supply [91]. Studies have demonstrated the efficacy of
treatment with glucocorticoids in enhancing neurological re-
covery and ameliorating the extent of brain edema [92].
I/R injury activates pro-inflammatory mediators like IL-6,
8 and TNF-a which contribute to neurological damage [93].
Pro-inflammatory cytokines induce demyelination and re-
cruitment of neutrophils which aggravates brain injury [94,
95]. Glucocorticoids have anti-inflammatory properties which
counteract the inflammatory response to reperfusion injury
[96]. Studies have shown that glucocorticoid administration
inhibit the expression of pro-inflammatory TNF-a [97]. Addi-
tionally, in another study glucocorticoids reduced the expres-
sion of pro-inflammatory mediators like IL-6, 8 and enhanced
brain function [98].
Cerebral perfusion pressure in the early stages of brain
injury is determined mainly by mean arterial pressure
(MAP) [99]. Studies have shown that hypotension after CA
is associatedwith higher mortality [77, 99]. Also the improved
MAP in patients receiving glucocorticoids possibly contribut-
ed to improved neurological recovery by attenuating peri-
arrest cerebral ischemia. Glucocorticoid enhanced vascular
smooth muscle response to vasopressors contributing to in-
creased MAP [9].
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However, glucocorticoid supplementation leads to elevated
serum glucose levels and may induce neuronal damage [100].
Studies have shown that glucocorticoids exacerbate hypoxic
injury to neurons and impair glucose uptake and metabolism in
the brain [101]. The neuronal damage in the presence of hyper-
glycemia is believed to be related to intracellular lactic acidosis
leading to an increase in the formation of oxygen free radicals
[102]. Studies have shown that elevated blood glucose or
lactate levels on admission were predictive of unfavorable
neurologic recovery after CA [103]. Moreover, in another
study, the relatively higher blood glucose level during the
post-resuscitation period was positively correlated with a poor
outcome after CA [104]. Furthermore, hyperglycemia enhances
neutrophil infiltration in the brain after ischemia. Therefore,
hyperglycemia-enhanced inflammatory response to ischemia/
reperfusionmight contribute to the exacerbation of the ischemic
injury [105]. Due to the hyperglycemia- associated toxicity, an
adequate glycemic control and the use of intravenous insulin
might be warranted, especially in the cases when glucocorti-
coids are administered in the post-resuscitation period [9].
Conflicting results have been reported in the literature with
regard to the neuroprotective effects of glucocorticoids. Glu-
cocorticoids have an impact on both the survival and death of
neurons [106]. A systematic review of focal cerebral ischemia
failed to show any specific steroid related benefit or adverse
effect [107]. Moreover, two other studies reported that gluco-
corticoids did not improve neurological recovery following
CA [12, 47], while experimental studies failed to show any
evidence of neuroprotection. The over-activation of glucocor-
ticoid receptors in the hippocampus by glucocorticoids can be
detrimental, enhancing the toxic effects of hypoxia and caus-
ing apoptosis [108, 109]. There is also a study that has
reported an increase in cellular vulnerability to ischemia after
glucocorticoid administration [110]. Moreover, an ischemia-
evoked rise in glucocorticoid levels may compromise the
synaptic neuronal function after hypoxic injury [109]. Fur-
thermore, in another study, glucocorticoid supplementation
impaired neuronal integrity and function [111]. Schreiber
et al. reported that systemic corticosteroid administration
was associated with a transition to delirium in patients with
acute lung injury [112]. The heterogeneity in results regarding
glucocorticoids as neuroprotective agents could be attributed
to differences in ischemia duration, agents, dosing regimens,
route of administration and outcome measurements [113].
Further experimental and clinical studies of greater homoge-
neity must be conducted in order to investigate the role of
glucocorticoids in ischemic brain injury.
Conclusion
Glucocorticoids during and after CPR seem to confer benefits
with respect to ROSC rates and long term survival. The
efficacy of stress doses of glucocorticoids in reversing
postresuscitation shock is well documented. They maintain
hemodynamic stability and improve organ function by reduc-
ing I/R injury. However, the effects of glucocorticoids in CPR
remain controversial, especially in regards to the neurological
outcome. Large scale randomized controlled clinical trials
must be undertaken in order to further address low dose
glucocorticoid efficacy in CA. Moreover, high quality studies
should also determine the optimal steroid supplementation
doses, as well as the optimal serum steroid levels during
CPR and in the post-resuscitation phase.
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